Andere talen Seegene, Inc.

Aandelen

A096530

KR7096530001

Biotechnologie & Medisch Onderzoek

Slotkoers Korea S.E. Andere beurzen 04-12-2025			Variatie 5 dagen	Verschil t.o.v. 1 jan (%)
25.650,00 ^KRW	-0,97%		+1,99%	+12,50%

14/11	Seegene, Inc. rapporteert resultaten over derde kwartaal en eerste negen maanden van 2025	CI
14/08	Seegene, Inc. maakt resultaten bekend voor het tweede kwartaal en het eerste halfjaar afgesloten op 30 juni 2025	CI

Andere talen

Seegene, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025	14/11
Seegene and Springer Nature Open Applications for 2025-2026 Nature Awards MDx Impact Grants	02/09
Seegene, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2025	14/08
Seegene Swings to Loss in Q2	08/08
Seegene Q2 operating profit 3 billion won, swings to profit from year earlier	08/08
Seegene Unveils CURECA™ and STAgora™ at ADLM 2025, Advancing the Next Stage of Diagnostics	05/08
Seegene Inc. Unveils CURECA?? and STAgora?? At ADLM 2025, Advancing the Next Stage of Diagnostics	05/08
Seegene unveils the world's first unattended PCR automation, igniting a global diagnostic paradigm shift at ADLM 2025	23/07
Seegene Launches STAgora™, a New Platform for Infectious Disease Analytics	01/07
Seegene, Inc.'s Equity Buyback Plan Extended till December 30, 2026.	11/06
Seegene Q1 Operating Profit 14.8 Billion Won, Swings To Profit From Year Earlier	09/05
Seegene's CURECA(TM) Emerges as a Potential Game Changer in End-to-End PCR Automation	02/05
Seegene Announces Development of CURECA™, a Next-Generation Fully Automated PCR Solution Featuring Customizable Pre-treatment Automation	09/04
Seegene Inc. Announces Development of CURECA, A Next-Generation Fully Automated PCR Solution Featuring Customizable Pre- Treatment Automation	09/04
Seegene, Inc. Reports Earnings Results for the Full Year Ended December 31, 2024	20/03
Seegene, Inc. agreed to acquire Dandimeka.	26/02
Seegene, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024	14/11
/C O R R E C T I O N -- Seegene Inc./	28-10-24
Seegene Holds Partner Executive Roundtable with Microsoft, and Springer Nature, Accelerating its Technology-Sharing Initiative	24-10-24
Seegene and Werfen Finalize Partnership Agreement on Technology-Sharing Initiative	08-10-24
Seegene, Inc. and Werfen, S.A. Finalize Partnership Agreement on Technology-Sharing Initiative	08-10-24
Seegene, Inc.(KOSDAQ:A096530) dropped from FTSE All-World Index	23-09-24
Seegene Expands mpox RUO Product Lineups with Enhanced Detection Assays for Clade 1	09-09-24
Seegene and Springer Nature Launch Nature Awards MDx Impact Grants, to Innovate Syndromic PCR Diagnostic Assays	03-09-24
Seegene and Springer Nature Launch 'Nature Awards MDx Impact Grants' to Innovate Syndromic PCR Diagnostic Assays	02-09-24

Geen resultaten voor deze zoekopdracht

Al het nieuws Aanbevelingen van analisten Belangrijkste gebeurtenissen Insiders Transcripten Persberichten Officiële publicaties Andere talen Ideeën voor de handel MarketScreener-artikels MarketScreener-analyses

Andere talen Seegene, Inc.

Aandelen

A096530

KR7096530001

Biotechnologie & Medisch Onderzoek

Andere talen

Filters